Antiviral Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

Description

Persistence Market Research has recently released a comprehensive report on the global market for antiviral drugs. The report provides a detailed assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, offering insights into the market structure.

Antiviral Drugs Market - Key Insights:

Market Size (2024E): USD 65.5 Bn
Projected Market Value (2033F): USD 90.0 Bn
Global Market Growth Rate (CAGR 2024 to 2033): 3.6%

Antiviral Drugs Market - Report Scope:

Antiviral drugs play a critical role in the treatment of viral infections across various therapeutic areas, including HIV/AIDS, hepatitis, influenza, herpes, and COVID-19. These drugs inhibit the replication of viruses, thereby reducing the severity and duration of infections. The antiviral drugs market serves hospitals, clinics, retail pharmacies, and online pharmacies, offering a range of drug classes, including nucleoside analogues, protease inhibitors, polymerase inhibitors, and fusion inhibitors.

Market Growth Drivers:

The global antiviral drugs market is driven by several key factors, including increasing prevalence of viral infections, rising healthcare expenditures, and advancements in drug development. Technological innovations, such as the development of novel antiviral therapies and combination drug therapies, enhance treatment efficacy and patient outcomes. Moreover, the ongoing research in virology and molecular biology fuels the discovery of new antiviral drug targets and formulations, fostering market growth.

Market Restraints:

Despite promising growth prospects, the antiviral drugs market faces challenges related to viral resistance, high treatment costs, and regulatory hurdles in drug approval processes. Stringent regulations governing clinical trials and drug safety assessments impose compliance burdens on pharmaceutical companies, affecting market entry barriers and development timelines. Furthermore, limited reimbursement coverage for antiviral treatments and the emergence of drug-resistant viral strains pose challenges for market expansion, particularly in developing regions with limited access to healthcare resources.

Market Opportunities:

The antiviral drugs market presents significant growth opportunities driven by demographic trends, evolving healthcare delivery models, and pandemic preparedness initiatives. The integration of digital health technologies, such as telemedicine platforms and remote patient monitoring, enhances patient access to antiviral therapies and improves treatment adherence. Furthermore, the expanding application of antiviral drugs beyond traditional infectious diseases, including in oncology and immunology, broadens the market scope and stimulates innovation. Strategic partnerships, investment in research and development, and the introduction of affordable antiviral therapies are crucial to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the global antiviral drugs market?
Which drug classes and therapeutic areas are driving antiviral drug adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the antiviral drugs market?
Who are the key players contributing to the antiviral drugs market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global antiviral drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global antiviral drugs market, including Gilead Sciences, Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, and Roche Holding AG, focus on innovation, portfolio expansion, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop next-generation antiviral therapies, including broad-spectrum antiviral agents and RNA-targeted therapies, addressing unmet medical needs and emerging viral threats. Collaborations with research institutions, healthcare providers, and regulatory agencies facilitate drug development and market access. Moreover, emphasis on clinical research, patient education, and community outreach enhances market growth and supports public health initiatives in combating infectious diseases.

Key Companies Profiled:

Gilead Sciences Inc
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd
Merck & Co. Inc
AbbVie
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Cipla Inc.
Aurobindo Pharma
Dr. Reddy's Laboratories Ltd.

Market Segments Covered in Antiviral Drugs Market Analysis

By Drug Class

DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Other Drug Classes

By Type

Branded
Generics

By Application

HIV
Hepatitis
Herpes
Influenza
Other Applications

By Region

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Product Code: PMRREP33257

1. Executive Summary

1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Persistence Market Research Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

3.1. Risk Assessment
- 3.1.1. COVID-19 Crisis and Impact on Antiviral Drugs
- 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
- 3.1.3. Impact on Market Value (US$ Million)
- 3.1.4. Assessment by Key Countries
- 3.1.5. Assessment by Key Market Segments
- 3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends

4. Market Background

4.1. Antiviral Drugs Market, by Key Countries
4.2. Antiviral Drugs Market Opportunity Assessment (US$ Million)
- 4.2.1. Total Available Market
- 4.2.2. Serviceable Addressable Market
- 4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
- 4.3.1. Demand in optimistic Scenario
- 4.3.2. Demand in Likely Scenario
- 4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
- 4.4.1. Investment in Established Markets
  - 4.4.1.1. In Short Term
  - 4.4.1.2. In Long Term
- 4.4.2. Investment in Emerging Markets
  - 4.4.2.1. In Short Term
  - 4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
- 4.5.1. Top Companies Historical Growth
- 4.5.2. Growth in Automation, By Country
- 4.5.3. Patch Management Adoption Rate, By Country
4.6. Market Dynamics
- 4.6.1. Market Driving Factors and Impact Assessment
- 4.6.2. Prominent Market Challenges and Impact Assessment
- 4.6.3. Patch Management Market Opportunities
- 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

5.1. Manufacturers' Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking

6. Global Antiviral Drugs Market Demand Analysis 2019-2023 and Forecast, 2024-2033

6.1. Historical Market Analysis, 2019-2023
6.2. Current and Future Market Projections, 2024-2033
6.3. Y-o-Y Growth Trend Analysis

7. Global Antiviral Drugs Market Value Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Million) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Million) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2033
- 8.3.1. DNA Polymerase Inhibitors
- 8.3.2. Reverse Transcriptase Inhibitors
- 8.3.3. Neuraminidase Inhibitors
- 8.3.4. Protease Inhibitors
- 8.3.5. others
8.4. Market Attractiveness Analysis By Drug Class

9. Global Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Type

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Type, 2019-2023
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2024-2033
- 9.3.1. Branded
- 9.3.2. Generics
9.4. Market Attractiveness Analysis By Type

10. Global Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Application

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Application, 2019-2023
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2024-2033
- 10.3.1. HIV
- 10.3.2. Hepatitis
- 10.3.3. Herpes
- 10.3.4. Influenza
- 10.3.5. Other Applications
10.4. Market Attractiveness Analysis By Application

11. Global Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Region

11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
11.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2024-2033
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. Asia Pacific
- 11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region

12. North America Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
12.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2024-2033
- 12.4.1. By Country
  - 12.4.1.1. U.S.
  - 12.4.1.2. Canada
  - 12.4.1.3. Rest of North America
- 12.4.2. By Drug Class
- 12.4.3. By Application
- 12.4.4. By Type
12.5. Market Attractiveness Analysis
- 12.5.1. By Country
- 12.5.2. By Drug Class
- 12.5.3. By Application
- 12.5.4. By Type

13. Latin America Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
13.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2024-2033
- 13.4.1. By Country
  - 13.4.1.1. Brazil
  - 13.4.1.2. Mexico
  - 13.4.1.3. Rest of Latin America
- 13.4.2. By Drug Class
- 13.4.3. By Application
- 13.4.4. By Type
13.5. Market Attractiveness Analysis
- 13.5.1. By Country
- 13.5.2. By Drug Class
- 13.5.3. By Application
- 13.5.4. By Type

14. Europe Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
14.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2024-2033
- 14.4.1. By Country
  - 14.4.1.1. Germany
  - 14.4.1.2. France
  - 14.4.1.3. U.K.
  - 14.4.1.4. Italy
  - 14.4.1.5. Spain
  - 14.4.1.6. Russia
  - 14.4.1.7. Rest of Europe
- 14.4.2. By Drug Class
- 14.4.3. By Application
- 14.4.4. By Type
14.5. Market Attractiveness Analysis
- 14.5.1. By Country
- 14.5.2. By Drug Class
- 14.5.3. By Application
- 14.5.4. By Type

15. Asia Pacific Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
15.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2024-2033
- 15.4.1. By Country
  - 15.4.1.1. China
  - 15.4.1.2. Japan
  - 15.4.1.3. South Korea
  - 15.4.1.4. Australia
  - 15.4.1.5. India
  - 15.4.1.6. Rest of Asia Pacific
- 15.4.2. By Drug Class
- 15.4.3. By Application
- 15.4.4. By Type
15.5. Market Attractiveness Analysis
- 15.5.1. By Country
- 15.5.2. By Drug Class
- 15.5.3. By Application
- 15.5.4. By Type

16. Middle East and Africa Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
16.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2024-2033
- 16.4.1. By Country
  - 16.4.1.1. Saudi Arabia
  - 16.4.1.2. South Africa
  - 16.4.1.3. Israel
  - 16.4.1.4. Rest of Middle East and Africa
- 16.4.2. By Drug Class
- 16.4.3. By Application
- 16.4.4. By Type
16.5. Market Attractiveness Analysis
- 16.5.1. By Country
- 16.5.2. By Drug Class
- 16.5.3. By Application
- 16.5.4. By Type

17. Key Countries Antiviral Drugs Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
- 17.1.1. Market Value Proportion Analysis, By Key Countries
- 17.1.2. Global Vs. Country Growth Comparison
17.2. US Antiviral Drugs Market Analysis
- 17.2.1. Value Proportion Analysis by Market Taxonomy
- 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.2.2.1. By Drug Class
  - 17.2.2.2. By Application
  - 17.2.2.3. By Type
17.3. Canada Antiviral Drugs Market Analysis
- 17.3.1. Value Proportion Analysis by Market Taxonomy
- 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.3.2.1. By Drug Class
  - 17.3.2.2. By Application
  - 17.3.2.3. By Type
17.4. Mexico Antiviral Drugs Market Analysis
- 17.4.1. Value Proportion Analysis by Market Taxonomy
- 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.4.2.1. By Drug Class
  - 17.4.2.2. By Application
  - 17.4.2.3. By Type
17.5. Brazil Antiviral Drugs Market Analysis
- 17.5.1. Value Proportion Analysis by Market Taxonomy
- 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.5.2.1. By Drug Class
  - 17.5.2.2. By Application
  - 17.5.2.3. By Type
17.6. Germany Antiviral Drugs Market Analysis
- 17.6.1. Value Proportion Analysis by Market Taxonomy
- 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.6.2.1. By Drug Class
  - 17.6.2.2. By Application
  - 17.6.2.3. By Type
17.7. France Antiviral Drugs Market Analysis
- 17.7.1. Value Proportion Analysis by Market Taxonomy
- 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.7.2.1. By Drug Class
  - 17.7.2.2. By Application
  - 17.7.2.3. By Type
17.8. Italy Antiviral Drugs Market Analysis
- 17.8.1. Value Proportion Analysis by Market Taxonomy
- 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.8.2.1. By Drug Class
  - 17.8.2.2. By Application
  - 17.8.2.3. By Type
17.9. Spain Antiviral Drugs Market Analysis
- 17.9.1. Value Proportion Analysis by Market Taxonomy
- 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.9.2.1. By Drug Class
  - 17.9.2.2. By Application
  - 17.9.2.3. By Type
17.10. UK Antiviral Drugs Market Analysis
- 17.10.1. Value Proportion Analysis by Market Taxonomy
- 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.10.2.1. By Drug Class
  - 17.10.2.2. By Application
  - 17.10.2.3. By Type
17.11. Russia Antiviral Drugs Market Analysis
- 17.11.1. Value Proportion Analysis by Market Taxonomy
- 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.11.2.1. By Drug Class
  - 17.11.2.2. By Application
  - 17.11.2.3. By Type
17.12. China Antiviral Drugs Market Analysis
- 17.12.1. Value Proportion Analysis by Market Taxonomy
- 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.12.2.1. By Drug Class
  - 17.12.2.2. By Application
  - 17.12.2.3. By Type
17.13. Japan Antiviral Drugs Market Analysis
- 17.13.1. Value Proportion Analysis by Market Taxonomy
- 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.13.2.1. By Drug Class
  - 17.13.2.2. By Application
  - 17.13.2.3. By Type
17.14. South Korea Antiviral Drugs Market Analysis
- 17.14.1. Value Proportion Analysis by Market Taxonomy
- 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.14.2.1. By Drug Class
  - 17.14.2.2. By Application
  - 17.14.2.3. By Type
17.15. Saudi Arabia Antiviral Drugs Market Analysis
- 17.15.1. Value Proportion Analysis by Market Taxonomy
- 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.15.2.1. By Drug Class
  - 17.15.2.2. By Application
  - 17.15.2.3. By Type
17.16. South Africa Antiviral Drugs Market Analysis
- 17.16.1. Value Proportion Analysis by Market Taxonomy
- 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.16.2.1. By Drug Class
  - 17.16.2.2. By Application
  - 17.16.2.3. By Type
17.17. Israel Antiviral Drugs Market Analysis
- 17.17.1. Value Proportion Analysis by Market Taxonomy
- 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2033
  - 17.17.2.1. By Drug Class
  - 17.17.2.2. By Application
  - 17.17.2.3. By Type
- 17.17.3. Competition Landscape and Player Concentration in the Country

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies
18.2. Market Concentration
18.3. Market Share Analysis of Top Players
18.4. Market Presence Analysis
- 18.4.1. By Regional footprint of Players
- 18.4.2. Product footprint by Players

19. Competition Analysis

19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
- 19.3.1. Gilead Sciences Inc
  - 19.3.1.1. Overview
  - 19.3.1.2. Product Portfolio
  - 19.3.1.3. Sales Footprint
  - 19.3.1.4. Strategy Overview
- 19.3.2. GlaxoSmithKline plc
  - 19.3.2.1. Overview
  - 19.3.2.2. Product Portfolio
  - 19.3.2.3. Sales Footprint
  - 19.3.2.4. Strategy Overview
- 19.3.3. F. Hoffmann-La Roche Ltd
  - 19.3.3.1. Overview
  - 19.3.3.2. Product Portfolio
  - 19.3.3.3. Sales Footprint
  - 19.3.3.4. Strategy Overview
- 19.3.4. Merck & Co. Inc
  - 19.3.4.1. Overview
  - 19.3.4.2. Product Portfolio
  - 19.3.4.3. Sales Footprint
  - 19.3.4.4. Strategy Overview
- 19.3.5. AbbVie
  - 19.3.5.1. Overview
  - 19.3.5.2. Product Portfolio
  - 19.3.5.3. Sales Footprint
  - 19.3.5.4. Strategy Overview
- 19.3.6. Johnson & Johnson Services, Inc.
  - 19.3.6.1. Overview
  - 19.3.6.2. Product Portfolio
  - 19.3.6.3. Sales Footprint
  - 19.3.6.4. Strategy Overview
- 19.3.7. Bristol-Myers Squibb Company
  - 19.3.7.1. Overview
  - 19.3.7.2. Product Portfolio
  - 19.3.7.3. Sales Footprint
  - 19.3.7.4. Strategy Overview
- 19.3.8. Cipla Inc.
  - 19.3.8.1. Overview
  - 19.3.8.2. Product Portfolio
  - 19.3.8.3. Sales Footprint
  - 19.3.8.4. Strategy Overview
- 19.3.9. Aurobindo Pharma
  - 19.3.9.1. Overview
  - 19.3.9.2. Product Portfolio
  - 19.3.9.3. Sales Footprint
  - 19.3.9.4. Strategy Overview
- 19.3.10. Dr. Reddy's Laboratories Ltd.
  - 19.3.10.1. Overview
  - 19.3.10.2. Product Portfolio
  - 19.3.10.3. Sales Footprint
  - 19.3.10.4. Strategy Overview